6 completed, 2 terminated, 1 no longer available. 5 Phase 3, 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Completed 3, Terminated 2 |
| Phase 1 | 2 | Completed 2 |
| Phase 2 | 1 | Completed 1 |
Follow REL-1017: new trials by email Literature Review of REL-1017 trials Research Report on REL-1017
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as Adjunctive Treatment for MDD REL-1017, Placebo - Major Depressive Disorder, Depression | Phase 3 | Terminated | Levomecor Inc. | 27 | 2023-08-17 | 2026-07-10 |
| A Study to Assess the Efficacy and Safety of REL-1017 as Monotherapy for Major Depressive Disorder (MDD) REL-1017, Placebo - Major Depressive Disorder | Phase 3 | Completed | Relmada Therapeutics, Inc. | 232 | 2021-06-02 | 2024-03-26 |
| Safety of REL-1017 for Major Depressive Disorder REL-1017 - Major Depressive Disorder | Phase 3 | Completed | Relmada Therapeutics, Inc. | 627 | 2021-04-01 | 2025-02-11 |
| A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD) REL-1017, Placebo - Major Depressive Disorder, Depression | Phase 3 | Terminated | Levomecor Inc. | 236 | 2021-03-30 | 2026-07-10 |
| A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD) REL-1017, Placebo - Major Depressive Disorder | Phase 3 | Completed | Relmada Therapeutics, Inc. | 227 | 2021-01-08 | 2024-08-27 |
| Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg or 50 mg Daily of REL-1017 in MDD REL-1017, Placebo - Depressive Disorder, Major, Depressive Disorder, Treatment-Resistant | Phase 2 | Completed | Relmada Therapeutics, Inc. | 62 | 2018-05-11 | 2023-11-01 |
| Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of REL-1017 (d-Methadone) REL-1017, Placebo - Neuropathic Pain | Phase 1 | Completed | Relmada Therapeutics, Inc. | 24 | 2015-08-31 | 2018-08-20 |
| Safety, Tolerability and Pharmacokinetics of Single Ascending Doses of REL-1017 (d-Methadone) REL-1017, Placebo - Neuropathic Pain | Phase 1 | Completed | Relmada Therapeutics, Inc. | 42 | 2014-12-04 | 2019-08-01 |
| Individual Patient Esmethadone (REL-1017) Expanded Access Program REL-1017 - Major Depressive Disorder, Depression | No longer available | Relmada Therapeutics, Inc. | 2026-08-12 |
Depressive Disorder, Major (7) · Depression (4) · Neuralgia (2) · Depressive Disorder, Treatment-Resistant (1)
Relmada Therapeutics, Inc. (7) · Levomecor Inc. (2)
United States (6)
Marco Pappagallo, MD (4) · Paul Greene, PhD (2) · Maurizio Fava, MD (1)
PMID 34933568, PMID 36821775, PMID 38767937, PMID 38917366, PMID 39999772, PMID 41749468